Korean Drug Co. Ltd (014570) — Capital Reinvestment Ratio

Latest as of June 2026: 0.01x

Korean Drug Co. Ltd (014570) has a Capital Reinvestment Ratio of 0.01x as of June 2026, meaning it reinvests 0% of its operating cash flow (₩1.90 Billion) in capital expenditures (₩17.20 Million). Check 014570 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

₩1.90 Billion
KRW

Capital Expenditures

₩17.20 Million
KRW

Data as of

Jun 2026
Most recent filing

Korean Drug Co. Ltd Capital Reinvestment Ratio (2014–2025)

This chart tracks Korean Drug Co. Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Korean Drug Co. Ltd operating cash flow efficiency.

Annual Capital Reinvestment Ratio for Korean Drug Co. Ltd (2014–2025)

Year-by-year Capital Reinvestment Ratio for Korean Drug Co. Ltd from 2014 to 2025. See Korean Drug Co. Ltd (014570) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 0.04x ₩13.11 Billion ₩475.05 Million ▼ -83.1%
2024 0.21x ₩4.87 Billion ₩1.04 Billion ▼ -79.2%
2022 1.03x ₩5.91 Billion ₩6.09 Billion ▲ +691.9%
2021 0.13x ₩8.81 Billion ₩1.15 Billion ▲ +117.3%
2020 0.06x ₩12.33 Billion ₩738.47 Million ▼ -87.8%
2019 0.49x ₩6.21 Billion ₩3.05 Billion ▲ +118.8%
2018 0.22x ₩5.79 Billion ₩1.30 Billion ▼ -91.1%
2017 2.53x ₩447.20 Million ₩1.13 Billion ▲ +2077.4%
2016 0.12x ₩3.96 Billion ₩460.84 Million ▼ -18.8%
2015 0.14x ₩6.13 Billion ₩878.05 Million ▲ +18.7%
2014 0.12x ₩4.46 Billion ₩538.19 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow